Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.06 NOK | +0.95% | -1.85% | -17.83% |
Feb. 28 | Transcript : Thor Medical ASA, H2 2023 Earnings Call, Feb 28, 2024 | |
Feb. 14 | Thor Medical ASA Announces CEO Changes | CI |
Valuation
Fiscal Period: December | 2023 |
---|---|
Capitalization 1 | 301.3 |
Enterprise Value (EV) 1 | 259.5 |
P/E ratio | -8.49 x |
Yield | - |
Capitalization / Revenue | - |
EV / Revenue | - |
EV / EBITDA | -37,999,461 x |
EV / FCF | -7,433,565 x |
FCF Yield | -0% |
Price to Book | 1.11 x |
Nbr of stocks (in thousands) | 233,539 |
Reference price 2 | 1.290 |
Announcement Date | 3/21/24 |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2022 | 2023 |
---|---|---|
Net sales | - | - |
EBITDA | - | -6.829 |
EBIT | - | -7.16 |
Operating Margin | - | - |
Earnings before Tax (EBT) | - | -5.561 |
Net income 1 | -311.2 | -26.56 |
Net margin | - | - |
EPS 2 | -2.703 | -0.1520 |
Free Cash Flow | - | -34.91 |
FCF margin | - | - |
FCF Conversion (EBITDA) | - | - |
FCF Conversion (Net income) | - | - |
Dividend per Share | - | - |
Announcement Date | 3/21/24 | 3/21/24 |
Balance Sheet Analysis
Fiscal Period: December | 2022 | 2023 |
---|---|---|
Net Debt 1 | - | - |
Net Cash position 1 | 98.6 | 41.8 |
Leverage (Debt/EBITDA) | - | - |
Free Cash Flow | - | -34.9 |
ROE (net income / shareholders' equity) | - | -3.31% |
ROA (Net income/ Total Assets) | - | -2.03% |
Assets 1 | - | 1,307 |
Book Value Per Share 2 | 0.5500 | 1.160 |
Cash Flow per Share 2 | 0.8600 | 0.1800 |
Capex 1 | 5.63 | - |
Capex / Sales | - | - |
Announcement Date | 3/21/24 | 3/21/24 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
1st Jan change | Capi. | |
---|---|---|
-17.83% | 22.43M | |
-3.46% | 102B | |
+1.41% | 96.29B | |
+2.13% | 22.18B | |
-15.84% | 21.2B | |
-9.21% | 18.31B | |
-39.98% | 17.38B | |
-14.65% | 16.36B | |
+4.39% | 13.97B | |
+31.35% | 12.17B |
- Stock Market
- Equities
- TRMED Stock
- Financials Thor Medical